Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

In response

Gul Bano and Stephen Nussey
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.9-1-93a
Clin Med February 2009
Gul Bano
St George's University of London
Roles: Consultant in Diabetes and Endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Nussey
St George's University of London
Roles: Professor of Endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

We thank Bering and Devendra for their comments. We agree that further research into preservation of β-cell function is highly relevant to patients with LADY though, of course, it is no more important than that in any other area of diabetes.

While we agree that early insulin therapy may preserve β-cell function, we would argue that progressive decline due to T-cell mediated destruction in type 1 diabetes is the norm. Extrapolation from the data of Weng et al based on type 2 diabetes and published only recently in 2008 does not allow the comment that the patient's β-cell function may have ‘been left to deteriorate on sulfonylureas’.1 Nor would we accept that automatic early treatment with insulin is more likely to ‘prevent catastrophic outcomes such as diabetic ketoacidosis’ than proper patient education and a supply of Ketostix®. Indeed, the psychosocial gains for a teenager (and other family members) treated with oral agents while maintaining excellent glycaemic control (as judged by the HbA1c values stated) for four years should not be underestimated.2

It is clear that the patient's family history would have allowed her inclusion into research studies on the progression to type 1 diabetes and that, had she been so involved, she may well have been discovered earlier and, thus, have had a milder initial clinical course. We doubt, though, whether this justifies the cost of HLA typing outside of research studies especially when, as Bering and Devendra point out, the results are only as good as tossing a coin.3 With regard to antibody testing we concur with the views expressed but feel that the role of ZnT8 only recently described needs to be explored in additional studies.4

  • © 2009 Royal College of Physicians

Reference

  1. ↵
    Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on β-cell function and glyacemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371:1573–60.
    OpenUrl
  2. ↵
    Silverstein J, Klingensmith G, Copeland K et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186–212.doi:10.2337/diacare.28.1.186
    OpenUrlFREE Full Text
  3. ↵
    Steck AK, Bugawan TL, Valdes AM et al. Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes 2005; 54:2482–6.doi:10.2337/diabetes.54.8.2482
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104:17040–45.doi:10.1073/pnas.0705894104
    OpenUrlAbstract/FREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
In response
Gul Bano, Stephen Nussey
Clinical Medicine Feb 2009, 9 (1) 93-94; DOI: 10.7861/clinmedicine.9-1-93a

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In response
Gul Bano, Stephen Nussey
Clinical Medicine Feb 2009, 9 (1) 93-94; DOI: 10.7861/clinmedicine.9-1-93a
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Reference
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • JAK-inhibition as a therapeutic strategy for refractory primary systemic vasculitides
  • Response
  • Functional disorders and chronic pain
Show more Letters to the editor

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians